Valve and Structural Heart Disease

As one of the nation’s first and busiest structural heart programs, we offer comprehensive care for aortic, mitral, tricuspid and pulmonic valve interventions.

Expanding options for care

2024 Outcomes

Overview

Through our heart team approach, each patient is reviewed by a multidisciplinary team to provide a personalized treatment plan and maximize quality of life and outcomes.

Accomplishments

We participate in the ALIGN-AR trial, which uses a transcatheter approach for aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation.
While the hospital is a pioneer in transcatheter aortic valve replacement (TAVR), we also focus heavily on adult congenital heart disease, which includes percutaneous prosthetic valve repair, atrial septal device use, pulmonic replacement, anomalous vein issues, and both percutaneous and open surgical options, including treatment of hypertrophic obstructive cardiomyopathy.
We lead the nation in expertise with the Ross procedure, with three physicians capable of performing it.
Our valve and structural heart clinics continue to expand to increase the availability of comprehensive valve care in North Texas.

“Baylor Scott & White The Heart Hospital – Plano has always embraced innovation and disruptive technology, recognizing these as key to advancing science and expanding patient treatment options. We have become one of the leading hospitals for structural heart care by relentlessly focusing on high-quality, patient-centered care.”

Molly Szerlip, MD
Regional Medical Director, Structural Heart Programs

M-teer year-over-year growth

100

FY20

FY21

FY22

FY23

FY24

STRUCTURAL HEART OUTCOMES FY24

complication	Plano	m-teer registry average
In-house mortality	0%	1.5%
Stroke	0%	0.4%
Acute care kidney injury	0%	0.8%
Disabling bleeding	0%	0.9%
Atrial septal defect closure	0%	2.0%

TAVR Historical cumulative volume plano and denton

3,000

2,500

2,000

1,500

1,000

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

Innovations

Our valve and structural heart teams lead several national clinical trials that keep us at the forefront of medicine.

Strong focus on evaluating the latest generations of TAVR valves to expand treatment options for patients who haven’t typically been candidates.
The only hospital in the North Texas region using electrosurgery, a cutting-edge structural intervention, in both aortic and mitral leaflet division.
Initiated separate robotic aortic valve replacement to expand minimally invasive options for aortic valve surgery.
Continue to lead the way in mitral valve disease treatment through various clinical trials focusing on transcatheter mitral valve replacement technologies, to expand our program and provide treatment options for a broader range of patients.
Innovating care for tricuspid regurgitation as one of the TRISCEND II sites that performed the first two cases of transcatheter tricuspid valve repair in the US, which led to FDA approval.